Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jul 15;14:391. doi: 10.1186/1471-2334-14-391

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Campi-Azevedo et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Immunogenicity and Viremia kinetics following 17DD-YF primary vaccination with different doses (27,476 IU-current; 10,447 IU; 3,013 IU; 587 IU; 158 IU and 31 IU). (A) Anti-YF neutralizing antibody titers (• = current dose and fades for subdoses) were measured by PRNT assay carried out 26–34 days (D30) after primary vaccination, as described in Methods. PRNT antibody titers are expressed in log₁₀ mIU/mL and 2.7 log₁₀ mIU/mL as the cut-off point to segregate seropositive from seronegative samples. Significant seropositivy rates (>95%) are highlighted by gray rectangle. (B) Viremia ( = current dose and fades for subdoses) was quantified by Real-time PCR at D3, D4, D5, D6 and D7 after primary vaccination as described in Methods. Viremia results are expressed in copies/mL. Kinetics profiles equivalent to current dose (27,476 IU) are highlighted by gray rectangle. The peaks of fold changes along the timeline were also taken into account as a relevant feature for equivalence assessment and highlighted by *.

Inline graphic — Immunogenicity and Viremia kinetics following 17DD-YF primary vaccination with different doses (27,476 IU-current; 10,447 IU; 3,013 IU; 587 IU; 158 IU and 31 IU). (A) Anti-YF neutralizing antibody titers (• = current dose and fades for subdoses) were measured by PRNT assay carried out 26–34 days (D30) after primary vaccination, as described in Methods. PRNT antibody titers are expressed in log₁₀ mIU/mL and 2.7 log₁₀ mIU/mL as the cut-off point to segregate seropositive from seronegative samples. Significant seropositivy rates (>95%) are highlighted by gray rectangle. (B) Viremia ( = current dose and fades for subdoses) was quantified by Real-time PCR at D3, D4, D5, D6 and D7 after primary vaccination as described in Methods. Viremia results are expressed in copies/mL. Kinetics profiles equivalent to current dose (27,476 IU) are highlighted by gray rectangle. The peaks of fold changes along the timeline were also taken into account as a relevant feature for equivalence assessment and highlighted by *.